Susceptibility genes in the pathogenesis of murine lupus by Nguyen, Charles et al.
S255
A glossary of specialist terms used in this chapter appears at the end of the text section. 
Available online http://arthritis-research.com/content/4/S3/S255
Introduction
SLE is a complex autoimmune disease of unknown etiol-
ogy. It is estimated to affect about 1 in 2000 people, and
the clinical presentation is highly variable and can some-
times be fatal, with a 10-year mortality rate of 28%. There
is a strong gender bias, with a female:male ratio of about
9:1 between the ages of 15 and 50 years. Ethnicity also
influences the incidence of the disease: African-Americans
and Hispanics are approximately two to four times more
likely to contract the disease than Caucasians [1,2].
SLE is primarily characterized by the production of auto-
antibodies directed against nuclear antigens such as
double-stranded DNA and chromatin. These antinuclear
autoantibodies (ANAs) cause end-organ damage by a
variety of mechanisms, notably via immune-complex-
mediated inflammation, which can result in glomerulo-
nephritis (GN), arthritis, rashes, serositis, and vasculitis. At
the molecular level, defects in both immune complex clear-
ance and in B-cell and T-cell tolerance and function have
been implicated in the pathogenesis of this disease [3].
A great deal of evidence supports a genetic basis for sus-
ceptibility to SLE. Estimates of the concordance rates in
monozygotic twins range between 25% and 69%, while
the rate is only 1–2% in dizygotic twins. The concordance
rate for the presence of ANAs in serum is as high as 92%
in monozygotic twins, and 10–12% of SLE patients have
first-degree or second-degree relatives with the disease
[4]. Stochastic processes and environmental influences
clearly also play a significant role in disease development
and exacerbation. These can include stress, bacterial and
viral infections, sun exposure, exogenous hormones and
certain drugs [2].
SLE rarely occurs as a result of a single gene mutation.
However, deficiencies in the early components of the
complement cascade can cause the phenotype: 95% of
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C1-deficient and C4-deficient people develop lupus, as
do 30% of people with C2 deficiency. In animal models,
disruption of Fas and Fas ligand (FasL) also has major
effects in disease susceptibility [5,6]. SLE more com-
monly occurs as a complex, polygenic disease, with many
MHC and nonMHC genes interacting with each other
and with the environment to create the varied disease
phenotypes [5,6].
No single gene has been found to be necessary or suffi-
cient to cause the disease. As with any multifactorial
disease, this complicates the identification of disease
genes. There is a low degree of penetrance associated
with individual susceptibility loci, and different combina-
tions of genes may be associated with disease develop-
ment in different families. In addition, the lack of any strong
selection against the susceptibility loci makes them fairly
common in the general population. This makes their detec-
tion by linkage analysis difficult in human populations,
which have a high degree of genetic variability. Nonethe-
less, several SLE susceptibility intervals have been identi-
fied in the human genome [7–9].
Animal models
A useful alternative strategy when dealing with genetically
complex diseases like SLE is the elucidation of disease
mechanisms in suitable animal models. These studies
often yield valuable insights that can then be applied to
human studies [10,11].
There are numerous synthetic murine models and sponta-
neous murine models of lupus (see Tables 1 and 2). The
synthetic models include transgenics and targeted gene
disruptions in which candidate disease genes that are
involved in a variety of lymphocytic interactions, apoptosis,
or antigen clearance are silenced or overexpressed
[12–14]. As might be expected, disrupting or enhancing
pathways involved in normal immune surveillance and
reactivity often results in autoimmunity.
In addition to synthetic mouse models, there are also
classic spontaneous models, including the (NZB × NZW)F1
(or NZB/W) mouse and the congenic recombinant
NZM2410 strain derived from this cross, the MRL/lpr
mouse, and the BXSB/yaa mouse. NZB/W mice develop
systemic autoimmunity with ANA production and immune-
complex-mediated GN, much like that seen in humans.
There is also a strong female gender bias in disease sus-
ceptibility, which is not seen in the NZM2410 strain. It is
thought that this may be due to the presence of very
strong susceptibility alleles in the NZM2410 strain, which
cause a phenotype severe enough to mask the effects of
sex hormones [15]. The lpr mutation of the Fas gene,
which is involved in apoptosis, is a strongly potentiating
factor for autoimmunity. In combination with a susceptible
genome, it causes systemic disease in MRL/lpr mice. In
the case of BXSB mice, the Y-linked autoimmune acceler-
ator gene causes severe disease in males when
expressed in the susceptible BXSB genome.
Table 1
Synthetic murine models of lupus
Model [reference] Affected function
Fas [42], FasL [43], Bcl2 [44] Regulation of apoptosis
Sap [25], C1q [26], C4 [27], DNAse [28] Clearance of antigen, such as apoptotic bodies and DNA
Ctla-4 [30], p21 [32], PD-1 [33], Lyn [38–40], Fyn [41] Activation and regulation of T cells
BLyS [35–37], PD-1 [33], Lyn [38–40], Fyn [41], FcγRIIB [51] Activation and regulation of B cells
FcγRIII [53], ICAM-1 [46] Proinflammatory mechanisms
BLyS, B-lymphocyte stimulator; FasL, Fas ligand; ICAM-1, intracellular adhesion molecule-1.
Table 2
Spontaneous murine models of lupus
Model [reference] Properties
(NZB × NZW)F1, NZM2410, (SWR × NZB)F1 Develops antinuclear autoantibodies and glomerulonephritis that resembles human lupus; 
exhibits a complex inheritance
MRL/lpr [42], MRL/gld [43] Contains a single-gene mutation (Fas or Fas ligand) that leads to autoimmunity when 
expressed in MRL background
BXSB/yaa Contains the Y-linked autoimmune accelerator gene that causes a more severe disease in 
BXSB malesS257
Numerous linkage analyses have been carried out in each
of these strains to identify the chromosomal regions
responsible for mediating susceptibility to various compo-
nent phenotypes such as ANA production, splenomegaly,
and GN [14]. In each study, three or more loci were linked
to disease susceptibility. This holds true in the case of the
(SWR × NZB)F1 strain. Mice of this strain also develop
disease very similar to that seen in NZB/W mice, and
linkage analysis has recently been carried out to under-
stand the contribution of the SWR genome to disease
susceptibility [16].
More than 50 loci have been found to affect susceptibility
to lupus or one of its component phenotypes [13,14],
pointing to the complexity and the polygenic nature of this
disease. Loci on chromosomes 1, 4, 7 and 17 have been
identified in multiple studies, which indicates that genes in
these regions may be important in immune regulation and
function, and may play a role in mediating disease in a
nonstrain-specific manner (Fig. 1). Many mapped loci co-
localize with regions linked to other autoimmune diseases
like insulin-dependent diabetes, experimental autoimmune
encephalomyelitis, and experimental induced arthritis in
various murine models [17]. This makes it probable that
certain loci affect autoimmune susceptibility in general by
modulating processes such as immune reactivity or apop-
tosis, while other genes play a role in determining the spe-
cific target organ and antigens involved in disease
pathogenesis.
Linkage analysis followed by congenic dissection is a
powerful strategy that is used to narrow identified regions
showing linkage to susceptibility, down to a point where
physical mapping and candidate gene analysis can be
meaningfully carried out. In congenic dissection, the
various genomic regions are moved individually onto a
resistant genome or vice versa, allowing one to see the
effects of each individual locus. Using this technique, sig-
nificant advances have been made towards identifying
genes that may be involved in the loss of tolerance to
nuclear antigens in the spontaneous models of murine
lupus. Linkage analysis of susceptibility to GN and ANA
production in the NZM2410 strain by Morel and Wake-
land identified three prominent loci [18], and congenic
strains were then made by moving each locus onto the
lupus-resistant C57Bl/6J (B6) background [19].
The B6.Sle1 congenic carries the Sle1 interval, found on
chromosome 1. The congenic is associated with the pro-
duction of autoantibodies against H2A/H2B/DNA sub-
nucleosomes and with the elevated expression of the
activation markers B7.2 on B cells and CD69 on CD4+
T cells [20]. B6.Sle2 harbors the Sle2 interval on chromo-
some 4 and shows a reduction in the threshold for activa-
tion of B cells, leading to the production of polyclonal IgM
and increased numbers of peritoneal and splenic B1 cells
when present on the B6 genetic background [21].
B6.Sle3, whose congenic interval lies on chromosome 7,
possesses an affected T-cell compartment, as well as the
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Figure 1
Genomic distribution of susceptibility intervals identified in linkage analysis on murine test crosses involving BSXB, MRL/lpr, PL/J, SWR, NZB,
NZW, and NZM2410 strains [14,60,62,63].S258
production of polyclonal IgG by B cells. These B6.Sle3
congenic mice also have an expansion of CD4+ T cells,
along with a decrease in activation-induced cell death of
these cells following stimulation with anti-CD3. The T cells
exhibit a stronger proliferative response in vitro to
T-dependent antigen stimulation, but not to T-independent
antigen stimulation [22].
Significantly, neither the Sle2 nor the Sle3 interval is suffi-
cient to cause the production of autoantibodies and kidney
disease on the lupus-resistant B6 background. When com-
bined with Sle1 as a bicongenic model, however, they
cause renal lesions and proteinuria with varying penetrance
[23]. This demonstrates the need for both an initiating
factor and the amplification of the immune response for
pathogenesis to occur. The Sle1 locus thus appears to be
an initiating factor in murine lupus that causes systemic
autoimmunity, resulting in GN when it is combined with
either the Sle2 or Sle3 loci in bicongenic strains of mice, or
with the BXSB-derived yaa gene [23].
Given the multiple loci that were identified in the
NZM2410 strain, the susceptibility to lupus is highly
complex. But to further complicate the issue, it was
recently discovered that there existed epistatic modifiers
or genes that suppress autoimmunity. Most of the Sle
intervals were derived from the NZW strain, which does
not have the significant autoimmune phenotype seen in
the NZM2410 strain [24].
Linkage analysis then confirmed that there existed four
suppressive loci, labeled ‘Sles’ (SLE suppressor), in the
NZW genome. The Sles1 locus, which is a specific sup-
pressor of Sle1, can in fact completely suppress the entire
autoimmune cascade that is caused by Sle1 on a
B6/NZW heterozygous background. This includes a pow-
erful humoral autoimmune response, and a high pene-
trance of fatal lupus nephritis (>75%). Sles1 is located on
chromosome 17, in the complement region of the murine
MHC. B6 mice congenic for both the Sle1 and the Sles1
intervals are phenotypically indistinguishable from B6
mice. Heterozygosity at the H2 locus has previously been
linked to lupus susceptibility in mouse models as well as
human lupus [12].
Sles2 is located on a region on chromosome 4 that was
previously shown to contain NZB-derived susceptibility
loci, and is linked to suppression of autoantibody produc-
tion. Sles3 on chromosome 3 is located near Il2, a region
that has been linked to diabetes and experimental auto-
immune encephalomyelitis susceptibility in murine models.
It is linked with humoral autoimmunity and, more weakly,
nephritis suppression. Sles4 on chromosome 9 is linked
with protection from nephritis but not humoral autoimmunity,
and its effect is entirely male specific [24]. These four sup-
pressive loci, along with the Sle loci, help illustrate the com-
plexity of SLE and the importance of epistatic interactions
among susceptibility genes in leading to autoimmunity.
Biological pathways
Pathway 1
Through component phenotypes detected via congenic dis-
section, the genes mediating lupus susceptibility in the
NZM2410 model can be organized into a hypothetical
pathway that provides the mechanisms for disease develop-
ment (Fig. 2). The first pathway requires a breach in toler-
ance to nuclear antigens. As mentioned previously, the Sle1
interval is associated with the production of autoantibodies
against H2A/H2B/DNA subnucleosomes [20]. Through the
use of bicogenic and tricongenic strains, the combination of
Sle1 with Sle2, Sle3, or yaa led to severe lupus nephritis,
indicating that Sle1 is the critical factor in the pathogenesis
of disease [23]. Furthermore, there are other numerous
genes, particularly those involved in antigen clearance, that
can potentially break tolerance to chromatin and can thus
be categorized into this first pathway.
The serum amyloid P component (SAP) is known to bind
the chromatin on surface blebs of apoptotic cells as well
as in released nuclear debris in a calcium-dependent
manner. Bickerstaff et al. have shown that the targeted
disruption of SAP in mice leads to an accelerated rate of
chromatin degradation when compared with SAP-suffi-
cient mice [25]. The SAP-deficient mice spontaneously
developed high titers of ANAs and severe GN. It has been
suggested that SAP seems to prevent the production of
autoantibodies against chromatin by binding to it and reg-
ulating its degradation and/or by sequestering it from
antigen receptors [25].
Early components of complement phenotypes are also
strongly associated with SLE. The first component of the
complement pathway, C1q, leads to the development of
autoimmunity when it is disrupted in the mouse. C1q-
deficient mice show high levels of ANAs as well as
increased numbers of apoptotic bodies in their glomeruli.
This accumulation of apoptotic bodies suggests that there
is a defect in the clearance of apoptotic debris [26]. C4
deficiency in mice has similarly been demonstrated to
cause high titers of ANAs, GN and splenomegaly. In addi-
tion, these mice accumulate activated T cells and B cells,
and there is impaired immune complex clearance [27].
DNase I is a major nuclease that may be involved in
removing DNA from apoptotic debris. Napirei et al. con-
structed a knockout model, and demonstrated ANA pro-
duction and GN [28]. DNase I is expressed at sites of high
cellular turnover such as the skin and gastrointestinal tract.
It is hypothesized that defective or decreased expression
of the enzyme may cause a buildup of DNA antigen,
leading to an increased risk of autoantibody formation.
Treatment of NZB/W mice with DNase I results in a
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decrease in the level of anti-DNA IgG, supporting such a
role for the molecule [29].
Pathway 2
The autoimmune response initiated by a breach in toler-
ance to self-antigen can be amplified by genes in the
second pathway that cause a dysregulation of the immune
response. Both Sle2 and  Sle3, mediating the abnormal
phenotypes in B cells and T cells, respectively, belong in
this second pathway. The B6.Sle1 congenic mouse does
not develop GN, and only when either Sle2 or Sle3 is
combined with the Sle1 loci in the bicongenic strain does
one see evidence of renal disease [23]. This vividly illus-
trates the notion that the breach in tolerance to nuclear
antigen does not lead to disease unless there is an amplifi-
cation of the autoimmune response, mediated by a dys-
regulated immune system.
In addition to Sle2 and Sle3, there are other molecules
that belong in the second pathway and that play important
roles in the activation or inhibition of lymphocytes. CTLA4
is a cell-surface molecule that, on binding to its ligand B7,
inhibits the CD28 costimulation of T cells. Mice that are
deficient in CTLA4 have been shown to have hyperprolif-
erative T cells and increased titers of serum antibodies
[30]. When anti-CTLA4 antibodies are administered to
NZB/W mice, the production of autoantibodies is inhibited
[31]. Another gene that regulates T-cell proliferation (and,
potentially, tolerance to self-antigen) is p21, a cyclin-
dependent kinase that is involved in the inhibition of cell-
cycle progression. p21-deficient mice were generated,
and they displayed T cells that had a hyperproliferative
response to sustained stimulation in vitro. Furthermore,
these mice developed a lupus-like syndrome with the
presence of ANAs as well as GN [32].
Another gene that may play a role in amplifying an auto-
immune response is PD-1, a cell-surface receptor that
belongs to the immunoglobulin superfamily and contains
an immunoreceptor tyrosine-based inhibitory motif. Mice
deficient in PD-1 develop an autoimmune phenotype char-
acterized by GN, which is further accelerated by the pres-
ence of the lpr mutation in the Fas gene. Although
expressed on a small percentage of cells in the thymus,
PD-1 becomes highly expressed on activated T cells and
B cells, and has been shown to inhibit the proliferative
response of primed T cells. It has been suggested that
this molecule may therefore play a role in maintaining
peripheral self-tolerance [33].
B-lymphocyte stimulator (BLyS), a member of the tumor
necrosis factor family of ligands, also plays an important
role in the immune system. It has been demonstrated to
enhance B-cell responses both in vitro and in vivo [34].
When overexpressed in transgenic mice, BLyS causes an
increase in the number of peripheral B cells and of auto-
antibodies directed against nuclear antigens, as well as in
GN and lymphadenopathy [35–37]. Furthermore, BLys
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Figure 2
Hypothetical pathways involved in the pathogenesis of SLE.S260
has been directly linked to murine lupus. Levels of circulat-
ing BLyS are elevated in the autoimmune NZB/W and
MRL-lpr/lpr mice during the onset and progression of
disease. When the mice were treated with an antibody
directed against one of the receptors for BLyS, kidney
disease was inhibited and mortality was reduced [37].
Lyn and Fyn are members of the src family protein tyrosine
kinases that transduce activating signals in B cells and T
cells. It has been demonstrated that mice lacking Lyn
develop a lupus-like syndrome, characterized by elevated
serum immunoglobulin levels and by the production of
autoantibodies that lead to GN [38–40]. The absence of
Fyn seems to accelerate the Lyn deficiency phenotype,
with mice deficient for both molecules developing
extremely severe lupus GN [41].
Apoptosis is an important process in the maintenance of
homeostasis in the immune system. Fas and FasL are both
cell-surface proteins that play critical roles in the regula-
tion of cell death. Their interaction with one another results
in rapid apoptosis of cells that bear Fas. The role of the
apoptotic process in maintaining tolerance has been
demonstrated in mice that are homozygous for the muta-
tions lpr [42] and gld [43] in the Fas and FasL genes,
respectively. These mice spontaneously develop severe
lymphadenopathy and produce T-cell-dependent autoanti-
bodies, indicating that Fas and FasL are important in regu-
lating T-cell tolerance.
A member of a family of anti-apoptotic genes, Bcl2, may
also be involved in autoimmunity through its role in B-cell
tolerance. Strasser et al. studied mice carrying a trans-
gene for Bcl2, and they demonstrated that the mice have
a large expansion of the B-cell compartment and sponta-
neously produce ANAs. A large percentage of them also
develop lupus-like GN. It was determined through FACS
analysis that this phenotype is not caused by the
increased proliferation of B cells, but by their prolonged
life spans [44].
Pathway 3
A third pathway in the development of lupus nephritis is
comprised of genes that potentiate end-organ damage.
When the loss of tolerance to chromatin and the contin-
ued production of autoantibodies due to a dysregulated
immune system occurs, genes such as Sle6 on chromo-
some 5 [24] and intracellular adhesion molecule-1
(ICAM-1) can target end-organ damage by the deposition
of immune complexes and the subsequent recruitment of
inflammatory mediators.
ICAM-1 is a member of the immunoglobulin superfamily of
adhesion receptors and, through its interaction with the β2
integrin LFA-1, it is believed to be involved in the recruit-
ment of lymphocytes to the kidney. It has been demon-
strated that ICAM-1 is upregulated in the kidneys from
MRL/lpr and NZB/W mice when compared with normal
mice [45]. MRL/lpr mice deficient in ICAM-1 show a
reduction in renal disease, as well as a remarkable
decrease in mortality [46]. The ICAM-1-deficient mice
exhibited less vasculitis in the kidney, lung, skin, and sali-
vary glands when compared with wild-type MRL/lpr mice,
supporting the idea that ICAM-1 may play an important
role in the pathogenesis of glomerular and vascular
damage in these mice.
In addition to Sle6 and ICAM-1, receptors for the IgG
class of antibodies, which play a variety of complex roles
in the immune system, also belong in the third pathway.
There are three major classes of Fc gamma receptors
present on cells of the immune system: FcγRI(CD64),
FcγRII(CD32), and FcγRIII(CD16). Fc gamma receptors
function in the noninflammatory clearance of immune com-
plexes from the circulation by mononuclear phagocytes in
the liver and spleen.
FcγRIIB has been found to be crucial to this process [47]
and, in accordance with its role in antigen clearance, mice
lacking this receptor have an increased susceptibility to
collagen-induced arthritis and Goodpasture’s syndrome,
which are both immune complex mediated [48–50].
FcγRIIB-deficient mice spontaneously develop autoanti-
bodies and GN in a strain-dependent manner [51]. Homo-
typic ligation of FcγRIIB on B cells sends a proapoptotic
signal, and this process has been postulated to help in the
maintenance of peripheral tolerance of B cells that have
undergone somatic hypermutation. Follicular dendritic
cells in germinal centers retain antigen in immune com-
plexes through FcγRIIB. B cells that interact with the
immune complex through both the B-cell receptor and
FcγRIIB survive, whereas those that do not see the
antigen through the B-cell receptor apoptose. This
enables selection against those B cells that bear very low
affinity, and therefore against potentially crossreactive
antigen receptors, pointing to a protective regulatory role
for FcγRIIB [52].
In contrast, FcγRIII seems to be more proinflammatory in
function. It can cause degranulation, phagocytosis, anti-
body-dependent, cell-mediated cytotoxicity, and cytokine
release on engagement, and it has been observed that the
deletion of FcγRIII actually has a protective effect on end-
organ damage in the autoimmune NZB/W strain. Mice
lacking these FcγIII receptors still produce autoantibodies,
deposit immune complexes, and activate complement, but
do not develop lupus nephritis [53].
Given the large number of susceptibility loci detected by
genome scans across various mouse strains, these three
pathways help define a mechanistic order with which the
pathogenesis of lupus occurs. Furthermore, identifying
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how a given disease gene functions via knockout and
transgenic technology provides a better understanding of
how the gene contributes to lupus and provides a better
approach for therapeutic intervention.
Fine mapping of Sle1 susceptibility loci
Linkage studies have provided a large collection of loci
linked to susceptibility to lupus. It is also notable from
Figure 1 that, although over 50 loci have been identified,
there appears to be multiple loci on chromosomes 1, 4, 7,
and 17 that have been identified in multiple studies. As
mentioned previously, many of the loci colocalize to
regions associated with other autoimmune diseases,
strongly indicating that a certain locus is involved in
autoimmunity. Furthermore, it is also becoming evident
that an individual locus may actually be a cluster of loci
that are associated with a spectrum of phenotypes, as in
the case with the Sle1 locus. Fine mapping of the NZW-
derived Sle1 locus revealed that it consists of at least four
closely linked, functionally related genes that can each
cause a break in tolerance to chromatin: Sle1a, Sle1b,
Sle1c, and Sle1d. Analysis of recombinant mice carrying
the first three of these loci showed that these subcon-
genic intervals are associated with phenotypes that are
very similar to each other and to the overall Sle1 pheno-
type, but are subtly different from one another [54].
Sle1a is an approximately 1 cM interval that is associated
with the production of ANAs specific for H2A/H2B/DNA,
but is not associated with increased CD69 or B7.2
expression. Mice of this strain have reduced numbers of T
cells, and a moderate increase in B220+ cells. The CD4+
T cells have a more activated phenotype than in B6 mice,
and there is a higher proportion of cells with a memory
phenotype. There is an increased IgG, but not IgM,
response to ovalbumin immunization. Thus, when isolated
from the other subcongenic loci, Sle1a was found to have
phenotypes that were masked in the entire Sle1 interval.
The 0.4 cM Sle1b  locus has the highest penetrance of
ANA production of the three subcongenic mouse strains,
with the same subnucleosomal specificity as that of the
entire interval. It also has the earliest age of onset of
autoantibody production. Sle1b is the only subinterval to
exhibit the female gender bias seen in Sle1 and to have an
increase in total IgM and IgG levels over B6. It also shows
the increased expression of CD69 and B7.2 seen in Sle1,
suggesting that it is the strongest contributor to the overall
phenotype of the chromosome 1 interval. The combination
of Sle1a  with Sle1b  was equivalent to the entire Sle1
interval with respect to ANA production, whereas the
region between the two loci by itself did not produce an
autoimmune phenotype above background levels. This
would indicate that the two loci together have a synergis-
tic effect, which is not caused by a gene that lies in the
interval between them [54].
The Sle1c locus is an approximately 3 cM interval. Unlike
Sle1a and Sle1b, Sle1c does not show specificity for any
one component of chromatin and shows no difference from
B6 in IgM response or IgG response to ovalbumin immu-
nization. Sle1c does not have an increased level of activa-
tion markers CD69 and B7.2, but it has an increased
proportion of CD4+ T cells with a memory phenotype.
It has been shown that B6 mice and NZW mice have dif-
ferent alleles of the Cr2 gene, which lies within the Sle1c
locus. This gene encodes the complement receptors 1
and 2 as separate splice variants. Complement receptors
1 and 2 bind antigen-bound degradation products of the
complement components C3 and C4. SLE patients have
lower levels of these receptors on their B cells [55], as do
MRL/lpr mice, prior to disease onset [56]. This indicates
that lowered expression of these receptors may play a role
in pathogenesis. One of the single nucleotide polymor-
phisms between the B6 and NZW alleles of Cr2 occurs in
the ligand-binding domain and introduces a novel glycosy-
lation site in the NZW allele. This results in lower ligand-
binding affinity, probably by interfering with receptor
dimerization. Complement receptor 1/complement recep-
tor 2-mediated signaling is lower in B cells carrying this
allele, and cells are also impaired in their response to T-
dependent antigens [57]. It has been shown that comple-
ment receptors may play an important role in maintaining
both central and peripheral B-cell tolerance [58]. Hence,
the lowered functioning of these receptors may allow
autoreactive B cells to escape tolerance, leading to the
ANA production phenotype.
Congenic dissection has also been applied to the Nba2
locus, which maps to the same region on chromosome 1 as
does Sle1. This NZB-derived region of about 8 cM is con-
tained in the 30 cM congenic interval in the B6.Nba2 con-
genic strain. Females of this strain develop IgG antibodies
to chromatin, to double-stranded DNA, and to total his-
tones. When crossed with NZW, female (B6.Nba2X-
NZW)F1 mice develop ANAs and proteinuria, and they die
from nephritis with a high frequency. This again points to the
possibility that the loss of tolerance to the chromatin
pathway may be an initiating factor in overall disease
development. Microarray analysis carried out on spleen cells
of preautoimmune mice of the congenic strain showed that,
of 11,000 genes analyzed, two interferon-responsive genes
belonging to the Ifi200 gene cluster showed a highly signifi-
cant difference in expression from B6 spleen cells. Both of
these genes mapped within the Nba2 locus. Ifi202, which
inhibits apoptosis when overexpressed and may play a role
in transcriptional regulation [36], was expressed at much
higher levels in B6.Nba2  spleens, while Ifi203 was
expressed at lower levels. It has been postulated that either
molecule could underlie the Nba2 phenotype, which may be
found to correlate with additional genes within the same
locus as well, as in the case of Sle1 [59].
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The region of mouse chromosome 1 that contains Sle1
and Nba2 has consistently been implicated in studies of
murine models of systemic autoimmunity [12,60]. Other
loci that map here include NZB-derived Lbw7 and SWR-
derived Swrl-1. Significantly, the human region syntenic to
the telomeric region of chromosome 1 where this cluster
of murine susceptibility loci lies (1q22–1q44) has also
been linked to lupus susceptibility in genome wide scans
using a variety of ethnic groups [7–9,61]. Advances made
in identifying the susceptibility genes in this region could
yield valuable insights into the checks and balances that
usually operate in the immune system, which when they
fail can result in a breach in tolerance to self-antigens,
initiating an autoimmune cascade.
Concluding remarks
The inheritance of lupus susceptibility is undoubtedly
complex and, although numerous susceptibility loci have
so far been identified, piecing them together into a mean-
ingful pathway that illustrates the pathogenesis of the
disease is very difficult. It is becoming evident through
congenic dissection that there is a strong genetic inter-
action among multiple loci that leads to the expression of
disease. A hypothetical model, containing three biologi-
cally distinct pathways, has been constructed that outlines
these genetic interactions and illustrates the progression
of lupus. The mechanisms within these pathways are still
poorly understood, however, and further work remains to
fully elucidate the pathogenesis of SLE.
Glossary of terms
ANA = antinuclear autoantibody; BLyS = B-lymphocyte
stimulator; FasL = Fas ligand; GN = glomerulonephritis;
SAP = serum amyloid P component; SLE = systemic
lupus erythematosus; Sles = SLE suppressor.
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tion, and the National Institutes of Health.
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